<DOC>
	<DOC>NCT02601235</DOC>
	<brief_summary>Prospective, randomized, open label, parallel , multicenter clinical study, controlled by active comparator ( 0.05 % Oxymetazoline Hydrochloride ) . The investigators hypothesis is that pediatric Naridrin® nasal solution is superior to 0.05 % Oxymetazoline Hydrochloride in improving nasal congestion. Participants aged 10-17 years with a clinical diagnosis of nasal congestion of allergic or inflammatory origin in at least one of the nostrils due to rhinitis or rhinopharyngitis will be included in the trial.</brief_summary>
	<brief_title>Clinical Study Evaluating the Efficacy and Safety of Pediatric Drugs in Improving Nasal Congestion.</brief_title>
	<detailed_description>Prospective, randomized, open label, parallel , multicenter clinical study, controlled by active comparator ( 0.05 % Oxymetazoline Hydrochloride) . The investigators hypothesis is that pediatric Naridrin® nasal solution is superior to 0.05 % Oxymetazoline Hydrochloride in improving nasal congestion. Participants aged 10-17 years with a clinical diagnosis of nasal congestion of allergic or inflammatory origin in at least one of the nostrils due to rhinitis or rhinopharyngitis will be included in the trial. The treatment period is 2 days.</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Pyrilamine</mesh_term>
	<mesh_term>Naphazoline</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<criteria>Participants aged 1017 years with clinical symptoms of nasal congestion of inflammatory or allergic origin in at least one nostril due to rhinitis or rhinopharyngitis ( cold and flu ); Participants who agree to participate in the study by signing and dating the informed consent form in duplicate ; Participants whose mother, father and / or legal guardian is in accordance with all study purposes and procedures, who have signed and dated two copies of IC, willing to adhere to treatment and attend scheduled appointments for the study; Participants with clinical symptoms of nasal congestion in at least one nostril as a diagnostic method using the Glatzel mirror ( nasal flow less than 2 cm in at least one nostril ) ; B negative urine HCG for female participants of childbearing potential . Participation in clinical trials in the last 12 months preceding the study (CNS Resolution 251 of August 7, 1997, Part III, subsection J), unless the investigator considers that there may be direct benefit to it; Total obstruction of one of the nostrils of other etiologies that are not inflammatory or allergic; Infectious bacterial disease (clinically diagnosed); Participants treated with antibiotic or possible antibiotic use due to another medical condition; Use of intranasal corticosteroids (7 days prior to the study) or systemic (15 days prior to the study), regarding the plasma halflife of the drug; Use of decongestants or antihistamine (intranasal or systemic) in the 03 days prior to the study; Use of inhaled drugs (except nasal moisturizers such as saline) or treatment with immunosuppressants in the week before the study; Participants with septum deviation grade II and III, nasal polyps, severe turbinate hypertrophy, adenoid hypertrophy, or other determining factors of nasal obstruction; Hyperthyroidism or hypertension or with known hypersensitivity to the components of the study drugs; History of transphenoidal hypophysectomy surgery or oronasal with exposure of the duramater; Exclusive mouthbreathers; Participants in chronic drug treatment for allergies (eg vaccines for allergy, cromolyn); History of alcohol abuse and / or drug 3 months before the study; Smokers Teens who are pregnant, breastfeeding or plan to become pregnant, or adolescents of childbearing potential who are not using a reliable method of contraception Presence of any medical or psychological condition that, at the discretion of the investigator, may prevent the individual from participating in the study.</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>rhinitis</keyword>
</DOC>